What Happened to Lithium? Antidepressant Augmentation in Clinical Settings
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Antidepressant augmentation is recommended when patients do not respond to antidepressant monotherapy. However, little is know about antidepressant augmentation in clinical settings and whether these practices reflect the research evidence. METHOD: The authors identified 244,859 patients in Veterans Administration mental health settings with a diagnosis of depression and an antidepressant prescription during fiscal year 2002. Patients with schizophrenia, dementia, or bipolar I disorder were excluded. The authors examined the prevalence and characteristics of antidepressant augmentation during the year, defined as receiving an antidepressant and an augmenting agent (lithium, second-generation antipsychotics, combinations of antidepressants, anticonvulsants, or "other") for >/=60 consecutive days in specified doses for those without other clinical indications. Mixed-effect models were used to examine predictors of augmentation. RESULTS: Some patients (22%) received an augmenting agent. The most commonly used agents were a second antidepressant (11%) and a second-generation antipsychotic (7%). Only 0.5% of the patients received lithium. Whites, younger patients, and those with a prior hospitalization were more likely to receive augmentation. African Americans were more likely to receive antipsychotic augmentation; whites were more likely to receive lithium. CONCLUSIONS: Antidepressant augmentation is common in clinical settings. Although lithium currently has the most research support, antipsychotic medications and a second antidepressant are the most widely used augmenting agents. Many augmenting agents are used across clinical and demographic groups. Research is needed on the relative effectiveness of these agents, along with efforts to promote the use of agents with the greatest level of research support.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DEFINITION AND EPIDEMIOLOGY OF TREATMENT-RESISTANT DEPRESSION
Fava, M., & Davidson, K. G. (1996) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(05)70283-5 · Cited by 797
Clinical correlates of inpatient suicide
Busch, K. A., Fawcett, J., & Jacobs, D. G. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0105 · Cited by 750
Cooper, L. A., Gonzales, J. J., Gallo, J. J., Rost, K. M., Meredith, L. S., Rubenstein, L. V., Wang, N.-Y., & Ford, D. E. (2003) · Medical Care · doi:10.1097/01.mlr.0000053228.58042.e4 · Cited by 651
Disparities in care for depression among primary care patients
Miranda, J., & Cooper, L. A. (2004) · Journal of General Internal Medicine · doi:10.1111/j.1525-1497.2004.30272.x · Cited by 317
A double-blind, placebo-controlled study of antidepressant augementation with mirtazapine
Carpenter, L. L., Yasmin, S., & Price, L. H. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01262-8 · Cited by 244
Barbosa, L., Berk, M., & Vorster, M. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0407 · Cited by 165
Research works printed but not linked: 24
- 10.7326/0003-4819-132-9-200005020-00011 · DOI · Paper page
- 10.1016/S0193-953X(02)00107-7 · DOI · Paper page
- American Psychiatric Association, 2000, Practice guideline for the treatment of patients with major depressive disorder (revision)
- Trivedi MH, 2000, Key T: Texas Implementation of Medication Algorithms (TIMA): Guidelines for Treating Major Depressive Disorder: TIMA Physician Procedure Manual
- 10.1016/S0193-953X(05)70195-7 · DOI
- 10.1177/070674370304800703 · DOI
- 10.1097/00004714-199910000-00006 · DOI · Paper page
- Baldessarini RJ, 2003, J Clin Psychiatry, 64, 44
- 10.1176/appi.ajp.160.1.1 · DOI · Paper page
- 10.1176/appi.ajp.158.1.131 · DOI · Paper page
- 10.1517/14656566.4.7.1175 · DOI
- 10.1016/S0924-9338(02)80447-3 · DOI
- 10.1016/j.biopsych.2003.08.007 · DOI · Paper page
- 10.1192/bjp.181.4.284 · DOI · Paper page
- 10.1016/0021-9681(87)90171-8 · DOI · Paper page
- 10.1177/070674370304800703 · DOI
- 10.1111/j.1749-6632.2001.tb05796.x · DOI · Paper page
- 10.4088/JCP.v61n0602 · DOI · Paper page
- 10.1176/appi.ajp.161.11.2060 · DOI
- 10.1038/oby.2004.46 · DOI
- Moore D, 2004, Jefferson J: Handbook of Medical Psychiatry
- Balsa AI, 2003, Am J Law Med, 29, 203, 10.1017/S0098858800002811 · DOI · Paper page
- 10.4088/JCP.v63n0802 · DOI
- 10.1176/appi.ajp.160.10.1817 · DOI · Paper page
Cited by
Akt/GSK3 Signaling in the Action of Psychotropic Drugs
Beaulieu, J.-M., Gainetdinov, R. R., & Caron, M. G. (2009) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.011008.145634 · Cited by 522
Role of GSK3β in behavioral abnormalities induced by serotonin deficiency
Beaulieu, J.-M., Zhang, X., Rodriguiz, R. M., Sotnikova, T. D., Cools, M. J., Wetsel, W. C., Gainetdinov, R. R., & Caron, M. G. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711496105 · Cited by 368
A β-arrestin 2 Signaling Complex Mediates Lithium Action on Behavior
Beaulieu, J.-M., Marion, S., Rodriguiz, R. M., Medvedev, I. O., Sotnikova, T. D., Ghisi, V., Wetsel, W. C., Lefkowitz, R. J., Gainetdinov, R. R., & Caron, M. G. (2008) · Cell · doi:10.1016/j.cell.2007.11.041 · Cited by 362
Inhibition of GSK3 by lithium, from single molecules to signaling networks
Freland, L., & Beaulieu, J.-M. (2012) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2012.00014 · Cited by 269
Henssler, J., Alexander, D., Schwarzer, G., Bschor, T., & Baethge, C. (2022) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2021.4313 · Cited by 111
Abou-Saleh, M. T., Müller-Oerlinghausen, B., & Coppen, A. J. (2017) · International Journal of Bipolar Disorders · doi:10.1186/s40345-017-0080-x · Cited by 74
“1% received an atypical antipsychotic (Valenstein et al. 2006).”
Metadata
- Authors
- Valenstein, M., McCarthy, J. F., Austin, K. L., Greden, J. F., Young, E. A., & Blow, F. C.
- Venue
- American Journal of Psychiatry
- Published
- 2006-07
- Volume
- 163
- Issue
- 7
- Pages
- 1219-1225
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2168193274
- Cited by
- 69
- References
- 6
- FWCI
- 3.96
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.